Attention A T users. To access the menus on this page please perform the following steps.
1. Please switch auto forms mode to off.
2. Hit enter to expand a main menu option (Health, Benefits, etc).
3. To enter and activate the submenu links, hit the down arrow.
You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.
Locator
Contact
Search
VA »
Health Care »
Pharmacy Benefits Management Services
»
VA Center For Medication Safety (VA MedSAFE)
Pharmacy Benefits Management Services
VA Center For Medication Safety (VA MedSAFE)
Bulletins And News Alerts
Alerts are based on the clinical evidence available at the time of publication. Recommendations are intended to assist practitioners in providing consistent, safe, high quality, and cost effective drug therapy. They are not intended to interfere with clinical judgment. When using dated material, the clinician should consider new clinical information, as available and applicable.
Safety Issue | Date of Release | Safety Information |
---|---|---|
Dolutegravir (Juluca, Tivicay, Triumeq) and Potential Risk for Neural Tube Defects | 05/31/2018 | National PBM Bulletin |
AMENDMENT-Accu-Chek Aviva Plus Health Network Strips Urgent Medical Device Correction | 05/22/2018 | National PBM Patient Level Recall Communication |
Acc-Chek Aviva Plus Health Network Strips Urgent Medical Device Correction | 05/18/2018 | National PBM Patient Level Recall Communication |
Heparin and Saline Syringe Recall Due to Contamination | 05/03/2018 | National PBM Patient Level Recall Communication |
Synthetic Marijuana and Potential Risk for Bleeding UPDATE | 04/20/2018 | National PBM Bulletin |
Synthetic_Marijuana_Potential_Risk_for_Bleeding_NATIONAL_PBM BULLETIN_FINAL_040518_with_disclaimer | National PBM Bulletin | |
Sofosbuvir/Velpatasvir (Epclusa) and Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Look-Alike/Sound-Alike Potential | 01/26/2018 | National PBM Bulletin |
Edaravone (Radicava™) and Potential for Leaking at Valve Site | 01/10/2018 | National PBM Bulletin |
Enoxaparin Sodium Injection: Recall Due to Incorrect Strength Syringe in Blister | 12/28/2017 | National PBM Patient Level Recall Communication |
Calcimimetic Therapy in Patients on Dialysis: Risk of Duplicate Therapy and Safety Considerations | 12/26/2017 | National PBM Bulletin |
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets : Recall Due to Possible Sub Potent and Super Potent Tablets | 12/05/2017 | National PBM Patient Level Recall Communication |
Febuxostat (Uloric): FDA Evaluates Risk of Cardiovascular Death | 11/21/2017 | National PBM Bulletin |
Afluria Pre-filled Syringe Label Creates the Potential for Confusion | 11/15/2017 | National PBM Bulletin |
Magic3® HydroSil Gripper and Personal Intermittent Catheters: Recall for Sterile Barrier Breach | 10/23/2017 | National PBM Patient Level Recall Communication |
Addendum - Procrit® (epoetin alfa) 1 mL Single-Dose, Preservative-Free Solution: Recall Due to Presence of Glass Particles | 09/25/2017 | National PBM Patient Level Recall Communication |
Medtronic Recall of MiniMed Infusion Sets Due to Potential Over-Delivery of Insulin | 09/18/2017 | National PBM Patient Level Recall Communication |
Procrit® (epoetin alfa) 1 mL Single-Dose, Preservative-Free Solution: Recall Due to Presence of Glass Particles | 09/01/2017 | National PBM Patient Level Recall Communication |
Lorazepam Oral Concentrate, USP 2mg/mL Recall Due to Misprinted Dosing Droppers Supplied with the Product | 08/23/2017 | National PBM Patient Level Recall Communication |
Magnesium Citrate Recall Due to Product Contamination | 08/17/2017 | National PBM Patient Level Recall Communication |
Leader Brand, Major Pharmaceuticals, and Rugby Laboratories Recall of ALL Liquid Products Manufactured by PharmaTech Due to B. cepacia Contamination Risk | 08/15/2017 | National PBM Patient Level Recall Communication |
Becton Dickinson - Insulin Syringes:Recall Due to Incorrect Product Labeling | 06/15/2017 | National PBM Patient Level Recall Communication |
Apixaban (Eliquis®) Recall Due to Incorrect Strength in Bottle | 06/08/2017 | National PBM Patient Level Recall Communication |
EpiPen and and EpiPen Jr Auto-Injector: Recall - Failure to Activate Device | 04/04/2017 | National PBM Patient Level Recall Communication |
Direct-Acting Antiviral Safety Issues | 03/14/2017 | National PBM Bulletin |
ADDENDUM: Mirtazapine Tablets, USP 45mg – Ongoing Recall Due to Commingled Tablets | 03/08/2017 | National PBM Patient Level Recall Communication |
Mirtazapine Tablets, USP 45mg – Recall Due to Potential of Commingled Tablets | 03/07/2017 | National PBM Patient Level Recall Communication |
Alprostadil for Injection (Edex®) – Recall Due to Potential Lack of Sterility Assurance | 03/06/2017 | National PBM Patient Level Recall Communication |
Chlorhexidine Gluconate Safety | 02/07/2017 | National PBM Bulletin |
Liquid Products Recall (PharmaTech) Due to Potential Risk of Product Contamination | 10/12/2016 | National PBM Patient Level Recall Communication |
GlucaGen® HypoKit® (Novo Nordisk Inc.) Recall Due to Needle Detachment from Syringe | 09/14/2016 | National PBM Patient Level Recall Communication |
Eye Wash/Eye Irrigating Soutions Recall Due to Microbial Contamination | 09/09/2016 | National PBM Patient Level Recall Communication |
Topical Skin Products Recall Due to Microbial Contamination | 08/29/2016 | National PBM Patient Level Recall Communication |
Amikacin Recall Due to Particulate Matter in Vials | 08/08/2016 | National PBM Patient Level Recall Communication |
Bactroban (Mupirocin) Recall Expansion | 08/04/2016 | National PBM Patient Level Recall Communication |
Lithium Safety | 07/25/2016 | National PBM Bulletin |
Various Diabetic Test Strips Recall (specific sites only) | 07/12/2016 | National PBM Patient Level Recall Communication |
Contaminated Oral Liquid Docusate | 06/29/2016 | National PBM Patient Level Recall Communication |
Fluoroquinolone Safety | 06/03/2016 | National PBM Bulletin |
Ketoconazole Safety | 05/31/2016 | National PBM Bulletin |
Canagliflozin and Risk of Amputations | 05/31/2016 | National PBM Bulletin |
Antipsychotic Agents and Safety Issues | 05/13/2016 | National PBM Bulletin |
Metformin Revised Warnings | 04/18/2016 | National PBM Bulletin |
Thyrogen® (thyrotropin alfa for injection) Recall Due to Glass Particulates | 04/01/2016 | National PBM Patient Level Recall Communication |
Idelalisib Safety | 03/29/2016 | National PBM Bulletin |
Amikacin Recall Due to Glass Particulates | 03/15/2016 | National PBM Patient Level Recall Communication |
Noxafil (Posaconazole): Dosing Errors When Switching Between Different Oral Formulations | 01/13/2016 | National PBM Bulletin |
Bactroban (Mupirocin) Recall: ADDENDUM | 12/17/2015 | National PBM Patient Level Recall Communication |
OmniPod Insulin Management System Recall: ADDENDUM | 12/14/2015 | National PBM Patient Level Recall Communication |
Auvi-Q (epinephrine injection, USP) Recall - Potential Inaccurate Dosage Delivery | 10/30/2015 | National PBM Patient Level Recall Communication |
BD Syringes and Loss of Drug Potency: FDA Expands Warning - UPDATE | 09/23/2015 | National PBM Bulletin |
OmniPod Insulin Management System Recall | 09/15/2015 | National PBM Patient Level Recall Communication |
Allergan Ophthalmic Product Recall Due to Particulate Matter: ADDENDUM | 09/04/2015 | National PBM Patient Level Recall Communication |
Allergan Ophthalmic Product Recall Due to Particulate Matter | 09/02/2015 | National PBM Patient Level Recall Communication |
BD Syringes and Loss of Drug Potency | 08/31/2015 | National PBM Bulletin |
Adverse Cardiovascular Thrombotic Events with NSAIDs: FDA Strengthens Warning | 08/04/2015 | National PBM Bulletin |
Ketorolac Recall Due to Particles in Glass Vial: ADDENDUM | 07/02/2015 | National PBM Patient Level Recall Communication |
Nexium Recall Due to Bottle Containing Seroquel Instead | 06/24/2015 | National PBM Patient Level Recall Communication |
SGLT2 Inhibitors and Potential Risk for Acidosis | 05/22/2015 | National PBM Bulletin |
Ketorolac Recall Due to Particles in Glass Vial | 05/04/2015 | National PBM Patient Level Recall Communication |
Ferumoxytol and Risk of Serious Allergic Reactions | 04/28/2015 | National PBM Bulletin |
Amiodarone Use with Ledipasvir/Sofosbuvir (Harvoni) or Sofosbuvir (Sovaldi) Combined with Another Direct-Acting Antiviral and Bradycardia | 03/31/2015 | National PBM Bulletin |
UPDATE: Testosterone Products and Cardiovascular Safety | 03/26/2015 | National PBM Bulletin |
DAPT Trial and Risk of Non-Cardiovascular Death | 12/17/2014 | National PBM Bulletin |
Dimethyl Fumarate (Tecfidera) and PML Resulting in Death | 11/07/2014 | National PBM Bulletin |
Creon Recall Due to Presence of Capsule of Incorrect Strength in Bottle | 10/03/2014 | National PBM Communication |
Digoxin in Patients with Atrial Fibrillation: Potential Harms | 09/30/2014 | National PBM Bulletin |
UPDATE: Niacin Study Results and Implications | 08/29/2014 | National PBM Bulletin |
Acetaminophen Safety | 06/10/2014 | National PBM Bulletin |
Eszopiclone (Lunesta): Lowered Dose Recommendations Due to Next-Day Impairment | 05/28/2014 | National PBM Bulletin |
Adverse Neurologic Events and Epidural Corticosteroid Injections for Pain | 05/01/2014 | National PBM Bulletin |
Alli (orlistat) Recall Due to Product Tampering | 04/04/2014 | National PBM Communication |
Effexor and Venlafaxine Recall for Possible Presence of Tikosyn Capsules | 03/10/2014 | National PBM Communication |
Saxagliptin and Cardiovascular Safety | 02/18/2014 | National PBM Bulletin |
Testosterone Products and Cardiovascular Safety | 02/07/2014 | National PBM Bulletin |
ADDENDUM: Additional Lots Identified for Abbott Freestyle Glucose Test Strips Recall | 12/04/2013 | National PBM Communication |
Abbott FreeStyle Glucose Test Strips Recall | 11/29/2013 | National PBM Communication |
Regadenoson (Lexiscan) and Adenosine (Adenoscan): Risk of Heart Attack and Death | 11/29/2013 | National PBM Bulletin |
Imitrex STATdose System and Sumatriptan Succinate Injection Refill 6mg Recall | 11/22/2013 | National PBM Communication |
LMWHs and Increased Risk of Spinal Column Bleeding and Paralysis | 11/15/2013 | National PBM Bulletin |
Low Molecular Weight Heparins (LMWHs) and Increased Risk of Spinal Column Bleeding and Paralysis | 11/15/2013 | National PBM Bulletin |
Tigecycline (Tygacil) and Increased Risk of Death | 10/01/2013 | National PBM Bulletin |
Nova Max Glucose Test Strips Recall Due To Falsely Elevated Blood Glucose Results | 08/14/2013 | National PBM Communication |
Valproate Use During Pregnancy and Lower IQ in Children Exposed | 08/06/2013 | National PBM Bulletin |
Medtronic Recall of Reservoirs Used with Paradigm Insulin Pumps Due to Leaks | 07/23/2013 | National PBM Communication |
Hydoxyethyl Starch Solutions and Mortality and Acute Kidney Injury | 07/19/2013 | National PBM Bulletin |
Aspirin Lot Recalled for Containing Acetaminophen Instead | 07/01/2013 | National PBM Communication |
Prevnar 13 and Pneumovax 23: Medication Errors and Appropriate Use | 04/10/2013 | National PBM Bulletin |
Sodium Phosphate Enema and Fatal Outcome | 03/26/2013 | National PBM Bulletin |
Peginesatide Injection Recall and Anaphylaxis |
03/04/2013 |
National PBM Communication |
Dual Renin-Angiotensin Aldosterone System Blockade and Impaired Renal Function and Hyperkalemia | 02/12/2013 | National PBM Bulletin |
Rugby Ferrous Sulfate Recall Due to Bottle Improperly Containing Meclizine HCL 25 mg Tablets | 01/13/2013 | National PBM Communication |
Zolpidem and Proposed Lower Doses Due to Impaired Mental Alertness | 01/16/2013 | National PBM Communication |
Ondansetron 32mg Single IV Dose Market Withdrawal Due to Cardiac Risks | 12/05/2012 | National PBM Bulletin |
Dabigatran (Pradaxa®) and Packaging Error - Recall Due to Possible Compromise in Product Quality | 11/09/2012 | National PBM Communication |
Ameridose Recall of All Unexpired Product Line | 11/01/2012 | National PBM Communication |
ADDENDUM: Fungal Meningitis Outbreak and Additional Patient Notification | 10/18/2012 | National PBM Communication |
Compounded Epidural Steroid Injections and Meningitis Outbreak | 10/05/2012 | National PBM Communication |
Citalopram (Celexa®) and Dose-Dependent QT Interval Prolongation: UPDATED RECOMMENDATIONS | 04/17/2012 | National PBM Bulletin |
Lo/Ovral-28 and Norgestrel/Ethinyl Estradiol Tablets - Recall for Inexact Tablet Counts or Out of Sequence Tablets | 02/03/2012 | National PBM Communication |
Aliskiren: Adverse Drug Events When Concomitantly Used with ACE Inhibitors or ARBs in Patients with Type II DM | 01/13/2012 | National PBM Bulletin |
Dronedarone and Cardiovascular Events in Permanent Atrial Fibrillation | 01/10/2012 | National PBM Communication |
Lexiscan® (Regadenoson) Update: New Safety Labeling Changes Approved By FDA | 11/15/2011 | National PBM Communication |
Target Dose of Angiotensin II Receptor Antagonists in Patients with Heart Failure | 10/31/2011 | National PBM Communication |
Citalopram Hydrobromide (Celexa®) and Dose-Dependent QT Interval Prolongation: UPDATE | 09/29/2011 | National PBM Bulletin |
Oral Contraceptives and Packaging Error Recall | 09/21/2011 | National PBM Communication |
Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease (CKD) and New Dosing Recommendations | 08/09/2011 | National PBM Communication |
Dronedarone (Multaq®) and Risk of Death and Serious CV Events in Patients with Permanent AF | 07/28/2011 | National PBM Communication |
Colistimethate for Injection and Dosing Confusion | 07/08/2011 | National PBM Bulletin |
Recall of Butalbital, APAP, and Caffeine Tablets and Hydrocodone Bitartrate and APAP Tablets – Mislabeling | 06/30/2011 | National PBM Communication |
Churchill Medical Skin-Prep Wipes Recall Due to Bacterial Contamination | 06/17/2011 | National PBM Communication |
SimplyThick Thickening Gel Products Recall and Possible Presence of Bacteria | 06/10/2011 | National PBM Communication |
Simvastatin: Updated Restrictions, Contraindications and Dose Limitations | 06/09/2011 | National PBM Bulletin |
ADDENDUM: Warfarin and High PotencyEXPANDED Recall | 06/02/2011 | National PBM Communication |
ADDENDUM: Smith & Nephew Various Adhesive Remover Wipes and Potential ContaminationRECALL | 05/31/2011 | National PBM Communication |
Nitroglycerin Tablets and Packaging Error Recall | 05/25/2011 | National PBM Communication |
Smith & Nephew Various Adhesive Remover Wipes and Potential Contamination RECALL | 05/20/2011 | National PBM Communication |
Marcaine Incorrect Labeling and Potential Look-Alike Confusion | 05/13/2011 | National PBM Bulletin |
Warfarin and High Potency Recall | 05/12/2011 | National PBM Communication |
Citalopram and Finasteride Recall Due to Mislabeling | 03/31/2011 | National PBM Communication |
Povidine® Iodine Prep Pads and Potential Microbial Contamination Recall | 03/29/2011 | National PBM Communication |
Dexamethasone Sodium Phosphate Inj USP 4mg/ml and Particulate Formation Recall | 03/23/2011 | National PBM Communication |
PPIs: Long-Term Use and Risk of Hypomagnesemia | 03/11/2011 | National PBM Communication |
Dicyclomine and Doxycycline LASA Confusion | 03/10/2011 | National PBM Bulletin |
Maternal and Newborn Risks with Certain Medications Used During Pregnancy | 03/09/2011 | National PBM Communication |
Albuterol Sulfate Inhalation Solution Recall- Packaging Error | 02/11/2011 | National PBM Communication |
Dronedaraone and Liver Injury | 01/27/2011 | National PBM Communication |
Triad Group Recall – Sterile Lubricating Jelly and Alcohol Swabs | 01/20/2011 | National PBM Communication |
Abbott Glucose Test Strips Recall | 12/28/2010 | National PBM Communication |
Propoxyphene and Cardiac Toxicity | 11/19/2010 | National PBM Bulletin |
Dronedaraone and Adverse Events Reported in ISMP | 11/15/2010 | National PBM Communication |
Epoetin Alfa (Epogen and Procrit) Voluntary Recall | 09/28/2010 | National PBM Communication |
Regadenoson (Lexiscan) and Updated Labeling | 09/22/2010 | National PBM Communication |
New Considerations for the Safe and Effective Use of Colchicine | 07/15/2010 | National PBM Bulletin |
Heparin and Potency Variation: UPDATE | 04/07/2010 | National PBM Communication |
Clopidogrel and Boxed Warning Regarding Poor Metabolizers | 03/25/2010 | National PBM Bulletin |
LABA Safety in Asthmatic Patients | 03/09/2010 | National PBM Communication |
Clopidogrel and Omeprazole Drug Interaction | 02/12/2010 | National PBM Bulletin |
Natalizumab and the Risk for Developing PML and IRIS | 02/09/2010 | National PBM Bulletin |
Sirolimus Monitoring | 01/22/2010 | National PBM Bulletin |
Safety of High Dose Statin-Fibrate Combinations | 11/10/2009 | National PBM Bulletin |
Influenza Vaccine Adverse Event Reporting | 10/19/2009 | National PBM Bulletin |
Heparin and Potency Variation | 10/02/2009 | National PBM Communication |
Sitagliptin and Acute Pancreatitis | 09/29/2009 | National PBM Communication |
Vitamin D: High Dose Use and Safety | 09/15/2009 | National PBM Bulletin |
Fentanyl Transdermal System Recall Due to Leaking Contents | 08/20/2009 | National PBM Communication |
Dextroamphetamine/Amphetamine 20mg Tablet recall Due to Weight Variability | 08/20/2009 | National PBM Communication |
Risk of Severe Hypoglycemia with Glyburide Use in Elderly Patients with Renal Insufficiency | 07/29/2009 | National PBM Bulletin |
Propofol and Urgent Drug Recall by Teva Due to Contaminated Lots | 07/14/2009 | National PBM Communication |
Medtronic and Quick-Set Infusion Sets Recall | 07/13/2009 | National PBM Communication |
Varenicline and Bupropion and Neuropsychiatric Adverse Events | 07/02/2009 | National PBM Communication |
Oxybutynin and Oxycodone and LASA Confusion | 07/02/2009 | National PBM Bulletin |
Citalopram and Tablet Size Variance Recall | 06/30/2009 | National PBM Communication |
Tacrine and Tacrolimus LASA Confusion | 06/25/2009 | National PBM Bulletin |
Leukotriene Inhibitors and Neuropsychiatric Adverse Events | 06/15/2009 | National PBM Communication |
TNF-a Blockers, including Simponi [golimumab], and Risk of Fungal Infections | 05/27/2009 | FDA MedWatch Safety Alert |
Macrodantin and Macrobid LASA Confusion | 05/06/2009 | National PBM Bulletin |
Regadenoson (Lexiscan) and Updated Labelling | 05/05/2009 | National PBM Communication |
Clevidipine and Propofol Potential Look-Alike Confusion | 04/30/2009 | National PBM Communication |
Ceftriaxone (Rocephin) and Calcium Interaction | 04/29/2009 | National PBM Communication |
Digoxin and Tablet Size Variability Recall | 04/02/2009 | National PBM Communication |
Infed (Iron Dextran) and Precipitate Formation Recall | 04/02/2009 | National PBM Communication |
Propafenone HCL 225mg (Watson) and Variability in Active Ingredient Recall | 03/30/2009 | FDA Recall - Firm Press Release |
Transdermal Patches Containing Metal and Risk of Burns | 03/05/2009 | FDA Public Health Advisory |
Rapitiva (Efalizumab) and PML | 03/03/2009 | National PBM Communication |
Metoclopramide and Risk of Tardive Dyskinesia | 02/26/2009 | FDA News |
Zonisamide (marketed as Zonegran, and generics) and Possible Metabolic Acidosis | 02/23/2009 | FDA Information for Healthcare Professionals |
Clopidogrel and Alteration of Effectiveness Due to CYP219 Inhibition | 01/29/2009 | National PBM Communication |
Duragesic Patch (50mcg/hr) and Cut in Drug Reservoir Recall | 12/31/2008 | Johnson and Johnson News |
Visicol and Osmoprep and Acute Phosphate Nephropathy | 12/19/2008 | National PBM Communication |
Methadone QTc Prolongation and Torsades de Pointes | 12/17/2008 | National PBM Communication |
LIFESCAN OneTouch SureStep Test Strips and Inaccurate Readings – RECALL | 12/04/2008 | National PBM Communication |
Phenytoin and Fosphenytoin and Serious Skin Reactions | 12/03/2008 | National PBM Communication |
Erlotinib (Tarceva) and Hepatic Impairment | 12/01/2008 | National PBM Communication |
ETHEX Recall | 11/14/2008 | National PBM Communication |
ETHEX Propafenone Recall Patient Letter | 11/12/2008 | National PBM Communication |
ETHEX Recall | 11/12/2008 | National PBM Communication |
Concentrated Opioid Solutions and Concentration Confusion | 11/12/2008 | National PBM Bulletin |
Natalizumab and PML | 10/31/2008 | National PBM Communication |
Varenicline and Increase in Reports of Serious Adverse Events | 10/28/2008 | National PBM Communication |
Iron Dextran and the Adverse Drug Events Associated with the High Molecular Weight Formulation | 10/21/2008 | National PBM Bulletin |
Calcium and Vitamin D and Change in Formulation | 10/06/2008 | National PBM Bulletin |
Look-Alike Error with Acetic Acid and Sterile Water Irrigation | 10/02/2008 | National PBM Bulletin |
Rituximab and PML | 9/19/2008 | National PBM Communication |
TNF Inhibitors and the Risk for Invasive Fungal Infections | 09/05/2008 | National PBM Bulletin |
EPOGEN® and Amgen Announcing Nationwide Voluntary Recall | 08/28/2008 | Patient Letter |
EPOGEN® and Amgen Announcing Nationwide Voluntary Recall | 08/28/2008 | National PBM Communication |
Natalizumab and PML | 08/27/2008 | National PBM Communication |
Ezetimibe/Simvastatin (Vytorin®), Simvastatin, and Ezetimibe (Zetia®) and Risk for Cancer | 08/26/2008 | National PBM Communication |
Naltrexone Injection Site Reactions | 08/20/2008 | National PBM Alert |
Exenatide (Byetta) and Hemorrhagic and Necrotizing Pancreatitis | 08/19/2008 | National PBM Response |
Simvastatin and Amiodarone Drug-Drug Interaction | 8/18/2008 | National PBM Response |
Mitoxantrone and Recommendations for Increased Monitoring | 8/18/2008 | National PBM Response |
PROCRIT® (EPOETIN ALFA) LOT NUMBER P114942A and Nationwide Voluntary Recall of Ortho Biotech | 8/8/2008 | National PBM Response |
PROCRIT® (EPOETIN ALFA) LOT NUMBER P114942A and Nationwide Voluntary Recall of Ortho Biotech – Patient Letter | 8/8/2008 | Patient Letter |
Erythropoiesis Stimulating Agents (ESAs ): FDA Labeling Changes for Cancer Patients Receiving Myelosuppressive Chemotherapy | 8/8/2008 | National PBM Update Alert |
Topical Thrombin and Safety Issues if Used Intravascularly | 8/7/2008 | National PBM Alert |
Bevacizumab Plus Sunitinib and Potential for Developing Microangiopathic Hemolytic Anemia | 7/31/2008 | National PBM Alert |
Micro-Bubble Contrast Agents (Definity® [Perflutren Lipid Microsphere] Injectable Suspension and Optison® [Perflutren Protein-Type A Microspheres] for Injection): Risk of Cardiopulmonary Reactions and Changes to Package Labeling | 7/18/2008 | National PBM Alert |
Nationwide Recall of Sodium Polystyrene Sulfonate Suspension, USP (15g/60ml) (NDC 0054-0165-51; Lot 856396A Expiration April 2010, and Lot 856693A ExpirationMay 2010) | 7/17/2008 | National PBM Alert |
Nationwide Recall of Sodium Polystyrene Sulfonate Suspension, USP (15g/60ml) (NDC 0054-0165-51; Lot 856396A Expiration April 2010, and Lot 856693A ExpirationMay 2010) | 7/17/2008 | Patient Letter |
Fluoroquinolone Use and the Potential for Tendinitis and Tendon Rupture | 7/10/2008 | National PBM Bulletin |
CellCept® (mycophenolate mofetil) and Cases of Progressive Multifocal Leukoencephalopathy (PML) | 7/1/2008 | National PBM Bulletin |
Varenicline (marketed as Chantix) and Recent Safety Issues | 6/20/2008 | Patient Letter (VA Secretary) |
Antipsychotic Use and Increase Risk of Death in Patients with Dementia-Related Psychosis | 6/16/2008 | FDA Information for Healthcare Professionals |
Becaplermin (Regranex) Safety Information and Labeling Changes | 6/11/2008 | National PBM Bulletin |
Tumor Necrosis Factor (TNF) Antagonists and the Development of Lymphomas and Other Cancers in Children and Young Adults (< 18 years) | 6/4/2008 | FDA Early Communication |
Varenicline (marketed as Chantix) and Recent Safety Issues | 5/30/2008 | National PBM Bulletin Addendum |
Varenicline (marketed as Chantix) and Recent Safety Issues | 5/30/2008 | VA Patient Letter |
Aprotinin (Trasylol®) and Increased Risk of Death and Other Serious Adverse Events – Temporary Suspension in Marketing | 5/16/2008 | National PBM Bulletin |
Use of Abacavir or Didanosine and Higher Risk of Heart Attack | 4/4/2008 | National HIV/AIDS Program Commentary |
Heparin Manufacturer Recalls | 4/2/2008 | B. Braun Internal Distribution Letter |
Heparin Manufacturer Recalls | 3/28/2008 | FDA Firm Press Release – Covidien Voluntary recall of Heparin Pre-Filled Syringes |
Use of Abacavir or Didanosine and Higher Risk of Heart Attack | 3/27/2008 | FDA Early Communication |
Heparin Manufacturer Recalls | 3/27/2008 | Advanced Medical Internal Distribution Letter |
Heparin Manufacturer Recalls | 3/21/2008 | Advanced Medical Manufacturer Letter |
Heparin Manufacturer Recalls | 3/25/2008 | Advanced Medical Important Notice |
Heparin Manufacturer Recalls | 3/21/2008 | FDA Firm Press Release for B.Braun Medical, Inc. |
Heparin Manufacturer Recalls | 3/20/2008 | B.Braun Urgent Drug Recall |
Update: Baxter Heparin Sodium Recall – Alternatives to Heparin Sodium | 3/19/2008 | Update |
Etanercept and Tuberculosis and Infections | 3/14/2008 | Dear Healthcare Professional Letter (Amgen) |
EPOGEN®/PROCRIT® and Aranesp® and Additional Trials Showing Increased Mortality and/or Tumor Progression | 3/7/2008 | Dear Healthcare Professional Letter (Amgen) |
Update: Baxter Heparin Sodium Recall | 3/3/2008 | Update B. Braun – April 2008 |
Calcium Supplements and Cardiovascular Disease in Older Women | 3/1/2008 | Review of a recent BMJ Article |
Baxter - Allergic Reactions to Heparin Sodium | 2/19/2008 | National PBM Bulletin |
Antiepileptic Drugs and Suicidality | 2/11/2008 | National PBM Bulletin |
Temsirolimus (Torisel®) Final Dose Concentration | 2/7/2008 | National PBM Bulletin Addendum |
Temsirolimus (Torisel®) Final Dose Concentration | 1/22/2008 | National PBM Bulletin |
Haloperidol and Cyanocobalamin 1ML Vials – Look-Alike Safety Alert | 12/20/2007 | National PBM Bulletin |
IV Haloperidol and Torsades de Pointe | 11/28/2007 | Updated Labeling |
Myfortic® (mycophenolic acid) and Increased Risks of Pregnancy Loss and Congenital Malformations / Change from Pregnancy Category C to Pregnancy Category D | 11/27/2007 | Dear Healthcare Professional Letter (Novartis) |
Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | FDA Early Communication |
Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | FDA Patient Information Sheet |
Varenicline (marketed as Chantix) and Suicidal Thoughts and Aggressive or Erratic Behavior | 11/20/2007 | PBM Update: Varenicline Safety |
Rosiglitazone and Increased Risk of Myocardial Ischemia | 11/19/2007 | FDA Information for Healthcare Professionals |
Erythropoiesis Stimulating Agents Safety Alert | 11/15/2007 | National PBM Bulletin Addendum |
Sildenafil (marketed as Viagra and Revatio) Vardenafil (marketed as Levitra) Tadalafil (marketed as Cialis) and Hearing Loss | 11/14/2007 | FDA Information for Healthcare Professionals |
Cefipime (marketed as Maxipime) and Increased Mortality | 11/14/2007 | FDA Early Communication |
Aprotinin (Trasylol®) and Increased Risk of Death and Other Serious Adverse Events – Temporary Suspension in Marketing | 11/6/2007 | National PBM Bulletin |
Codeine Use in Breast-Feeding Women | 10/9/2007 | National PBM Bulletin |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/28/2007 | National PBM Bulletin |
IV Haloperidol and Torsades de Pointe | 9/17/2007 | FDA MedWatch Summary |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/11/2007 | FDA Alert |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 9/11/2007 | Information for Healthcare Professionals (FDA) |
Viracept (nelfinavir mesylate) and presence of ethyl methanesulfonate (EMS), a process-related impurity | 9/10/2007 | FDA Drug Safety Information |
Entecavir (Baraclude® ) and potential for the development of HIV (human immunodeficiency virus) resistance in HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) | 8/16/2007 | Dear Healthcare Professional Letter (Bristol-Myers Squibb) |
Rosiglitazone and Risk of Heart Failure | 8/14/2007 | FDA Information for Healthcare Professionals |
Pioglitazone and Risk of Heart Failure | 8/14/2007 | FDA Information for Healthcare Professionals |
Omeprazole (Prilosec®) and Esomeprazole (Nexium®) and Cardiovascular Events | 8/9/2007 | Early Communication about an Ongoing Safety Review |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 8/1/2007 | Dear Healthcare Professional Letter (Roche) |
Omalizumab (Xolair®) and Anaphylactic Reactions | 7/10/2007 | National PBM Bulletin |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products | 7/5/2007 | FDA Alert |
Trimetrexate Glucuronate (Neutrexin®) and Drug Discontinuation | 3/16/2007 | Dear Healthcare Professional Letter |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products | 6/1/2007 | Dear Healthcare Professional Letter |
Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance) and Risk for Nephrogenic Systemic Fibrosis | 5/23/2007 | FDA Alert |
Rosiglitazone (Avandia®) and Cardiovascular Events | 5/22/2007 | Information for Healthcare Professionals |
Rosiglitazone (Avandia®) and Cardiovascular Events | 5/21/2007 | FDA Alert |
Rosiglitazone (Avandia®) and Cardiovascular Events | 5/21/2007 | FDA News |
Pergolide (Permax®) and Heart Valve Damage | 5/14/2007 | National PBM Bulletin |
Antidepressant Medications and New Warnings About Suicidal Thinking, Behavior in Young Adults | 5/2/2007 | FDA Press Release |
Ceftriaxone (Rocephin®) and Incompatibility with Calcium Products UPDATE | 5/1/2007 | Prescribing Information (Roche) |
Zolpidem (Ambien®) High Dose Use and Dose-Related Adverse Events | 5/1/2007 | Review of Various Trials Using Zolpidem at Higher Doses |
Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen | 4/5/2007 | Humira Pen and HumaPen; ISMP Newsletter |
Tegaserod and Discontinued Marketing for Safety Reasons | 4/3/2007 | National PBM Bulletin |
Methadone (Dolophine®) and Serious Side Effects | 4/1/2007 | Methadone Related Deaths; PBM Ez Minutes April-June 2007 |
Pergolide (Permax®) and Heart Valve Damage | 3/29/2007 | FDA Public Health Advisory |
Lamivudine and Zidovudine (Combivir®) Tablets and Counterfeit Labeling | 3/28/2007 | Dear Pharmacy Professional Letter |
Linezolid (Zyvox®) and Increased Mortality | 3/16/2007 | FDA Alert |
Linezolid (Zyvox®) and Increased Mortality | 3/16/2007 | Healthcare Professional Sheet |
Telithromycin (Ketek®) and Safety Issues | 3/1/2007 | Dear Healthcare Professional Letter |
Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | FDA Alert |
Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | FDA News |
Omalizumab (Xolair®) and Anaphylactic Reactions | 2/21/2007 | Healthcare Professional Sheet |
Telithromycin (Ketek®) and Serious Liver Toxicity | 2/12/2007 | FDA News – Label and Indication Changes |
Telithromycin (Ketek®) and Serious Liver Toxicity | 2/12/2007 | Questions and Answers on Telithromycin |
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 2/8/2007 | National PBM Bulletin |
IV Promethazine (Phenergan®) and Tissue Injury | 2/1/2007 | A Guidance on IV Promethazine Use and Safety Issues |
Erythropoiesis Stimulating Agents Safety Alert | 1/9/2007 | National PBM Bulletin |
Erythropoiesis Stimulating Agents Safety Alert | 1/9/2007 | Safety Concerns of Erythropoiesis Stimulating Agents |
Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen | 1/1/2007 | Two Pens Different Uses; PBM Ez-Minutes January-March 2007 |
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 1/1/2007 | Quinine Not for Leg Cramps Anymore; PBM Ez-Minutes January-March 2007 |
Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy | 12/18/2006 | FDA Alert |
Rituximab (Rituxan®) and Progressive Multifocal Leukoencephalopathy | 12/18/2006 | FDA Information for Healthcare Professionals |
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 12/11/2006 | FDA News |
Quinine and Unapproved Use for Leg Cramps Due to Serious Side Effects | 12/11/2006 | FDA Questions and Answers on Unapproved Quinine Products |
Methadone (Dolophine®) and Serious Side Effects | 11/30/2006 | National PBM Bulletin |
Methadone (Dolophine®) and Serious Side Effects | 11/30/2006 | VAMedSAFE Bulletin |
Methadone (Dolophine®) and Serious Side Effects | 11/27/2006 | FDA Alert |
Methadone (Dolophine®) and Serious Side Effects | 11/27/2006 | Healthcare Provider Information |
Oseltamivir Phosphate (Tamiflu®) and Precaution for Neuropsychiatric Events | 11/13/2006 | Dear Healthcare Professional Letter |
Fluarix® and Twinrix® Look-Alike Confusion Potential | 11/1/2006 | National PBM Bulletin |
Bevacizumab | 10/1/2006 | National PBM Bulletin |
Look-Alike Sound-Alike Vaccine Mix-ups: Adacel (Tdap) and Daptacel (DTaP) | 8/24/2006 | ISMP Newsletter |
IV Promethazine (Phenergan®) and Tissue Injury | 8/10/2006 | ISMP Newsletter |
Telithromycin (Ketek®) and Serious Liver Toxicity | 7/5/2006 | Questions and Answers on Telithromycin |
Telithromycin (Ketek®) and Serious Liver Toxicity | 6/29/2006 | FDA News for New Product Labeling Regarding Safety Issues |
Benzocaine | 2/28/2006 | A Guidance on the Use of topical Anesthetics for Naso/Oropharyngeal and Laryngotracheal Procedures |
Benzocaine | 2/10/2006 | FDA Public Health Advisory |
Benzocaine | 2/8/2006 | NCPS Patient Safety Alert |
Telithromycin (Ketek®) and Serious Liver Toxicity | 1/20/2006 | FDA Public Health Advisory |
Telithromycin (Ketek®) and Serious Liver Toxicity | 1/20/2006 | Questions and Answers on Telithromycin |
Benzocaine | 10/1/2005 | VAMedSAFE Patient Safety Issues – Benzocaine (Hurricaine Spray); PBM Ez-Minutes October-December 2005 |
Phosphodiesterase 5 Inhibitors and Loss of Vision | 8/5/2005 | National PBM Bulletin |
Clinical Guidance on Replacement Product Recommendations for Avandamet and Paxil CR in the VA | 3/29/2005 | National PBM Bulletin |
Vitamin E | 1/13/2005 | National PBM Bulletin |
Ethyl Chloride Safety Awareness | 1/1/2005 | Ethyl Chloride Ignites; PBM Ez-Minutes January-March 2005 |
Fentanyl Transdermal Patch | 12/22/2004 | National PBM Bulletin |
HIV Agents New on Formulary | 12/21/2004 | National PBM Bulletin |
Vitamin E | 12/1/2004 | VAMedSAFE Bulletin |
Vitamin E | 12/1/2004 | Background: High Dose Vitamin E (> 400IU/Day) |
Statins | 9/1/2004 | Statin-Fibrate Report – Focus on Safety |
Rofecoxib | 7/21/2004 | National PBM Bulletin |
Statins | 12/1/2001 | Recommendations for the Use of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors (statins) in Veteran Patients Receiving Medications with the Potential for Drug-Drug Interactions |
Oxycontin – Diversion and Abuse | 12/1/2001 |